InvestorsHub Logo
Followers 0
Posts 122
Boards Moderated 0
Alias Born 03/06/2020

Re: Empiricst1 post# 295647

Tuesday, 05/05/2020 7:34:02 PM

Tuesday, May 05, 2020 7:34:02 PM

Post# of 403475
an NBC story about a Pfizer,



Custom crafted immuno-oncology treatments have proven to be very expensive and have not fared well in the market place. The company which developed the first one approved by FDA, Dendreon, went bankrupt not long (within a year it seems to me) after approval.
Pfizer's partner in the CV vaccine stakes has a promising oncology candidate but not so much with virology. Hopefully they will do well under pressure.
" In both cases, however, the antiviral effects waned after less than a year, suggesting that improvements are needed to provide more robust and long-lasting immunity"
https://www.nature.com/articles/d41586-019-03072-8

what would be left for B, if that were so?
It is simply stunning how many people show up in ED'd wanting "a cure" or "a shot" to protect me/ my spouse/ my family from X or Y or Z and will accept nearly any intervention "as long as it's not a vaccine". They're the same folks who complain about measles outbreaks threatening their kids and become nearly rabid in their rants against "Medicine" for "not having developed a way to stave off these diseases".
Brilacidin therapy, if successful, would be God's gift to the above.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News